Physician profile
Jonathan Q Lam
NPI 1952362923
$6,792.25
in general payments reported to CMS, 2019-2025
48 companies · $1,376 in 2025
The $1,376 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $445 · 2021: $221 · 2022: $987 · 2023: $1,318 · 2024: $1,297 · 2025: $1,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,990.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $934.38 | 2020-2025 | |
| Lilly USA, LLC | $780.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $587.82 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $471.80 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.92 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $296.55 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $291.22 | 2019-2025 | Breztri, Airsupra |
| Pfizer INC. | $257.03 | 2020-2025 | |
| Amarin Pharma, INC. | $221.18 | 2019-2022 | |
| Gilead Sciences, INC. | $196.71 | 2019-2022 | |
| Astellas Pharma US INC | $186.33 | 2019-2025 | Veozah |
| Amgen INC. | $181.70 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $176.47 | 2019-2024 | Xarelto |
| Allergan, INC. | $154.05 | 2019-2020 | |
| Exact Sciences Corporation | $132.36 | 2023-2025 | Cologuard Collection Kit |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.